The COVID-19 pandemic in 2020 quickly changed how clinical trials are conducted. Many companies suddenly needed to switch to decentralized trial models to protect their studies and the safety of participants. Now the main question being asked is where do clinical trials go from here and what can we expect in 2021? And what does the future hold for emerging technologies, virtual trials, and patient centricity in the age of COVID?
In this webinar segment, Jeff Kasher of Patients Can’t Wait and Craig Lipset of Clinical Innovation Partners discuss how employees at sponsor companies and investigator sites are dealing with the explosion of new trial technologies and longer hours. Michelle Longmire of Medable also notes whether decentralized trials will be the new norm in the life sciences industry.